Werewolf Therapeutics (NASDAQ:HOWL) Issues Earnings Results, Misses Estimates By $0.03 EPS

Werewolf Therapeutics (NASDAQ:HOWL) released its quarterly earnings data on Tuesday. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.03), Zacks reports. Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 58.83%.

Werewolf Therapeutics Stock Performance

Werewolf Therapeutics stock traded down $0.01 during mid-day trading on Thursday, reaching $1.23. 48,965 shares of the stock traded hands, compared to its average volume of 266,069. The business’s 50-day moving average is $1.37 and its 200-day moving average is $1.82. Werewolf Therapeutics has a 12-month low of $1.03 and a 12-month high of $6.89. The company has a debt-to-equity ratio of 0.29, a current ratio of 10.10 and a quick ratio of 10.10. The stock has a market capitalization of $54.59 million, a PE ratio of -0.81 and a beta of 0.37.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on HOWL. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Werewolf Therapeutics in a research note on Wednesday. JMP Securities lowered their target price on shares of Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating on the stock in a research note on Tuesday, January 14th. Finally, Wedbush reissued an “outperform” rating and set a $8.00 price objective on shares of Werewolf Therapeutics in a report on Wednesday.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.